Melbourne (Australia) | 17 September 2024
Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET[1] agent, Zircaix®[2] (TLX250-CDx) for the imaging of kidney cancer in the United States (U.S.), subject to regulatory approval.
In preparation for a planned commercial rollout, Telix has contracted with Cardinal Health to enable Zircaix®2 availability across a wide range of U.S. locations.
Kevin Richardson, Chief Executive Officer, Telix Precision Medicine said, “We are pleased to build on our existing relationship with Cardinal Health to maximise patient access to this breakthrough product for non-invasive kidney cancer diagnosis. Through their extensive nuclear pharmacy network, which enables broad geographic reach and flexible scheduling, Cardinal Health has been central to the commercial success of Illuccix® PSMA-PET[3] imaging and we look forward to adding Zircaix®2 to their U.S. roster.”
Mike Pintek, President of Cardinal Health Nuclear & Precision Health Solutions, added, “This new agreement builds upon our successful relationship with Telix and our continued commitment to supporting innovative diagnostics and therapeutics addressing cancer patients today. Pending regulatory approval, our extensive commercial distribution infrastructure and expertise will facilitate reliable supply of Zircaix®2 throughout the U.S. to help diagnose kidney cancer.”
Commencement of the distribution agreement between Telix and Cardinal Health is subject to regulatory approval and includes industry-standard commercial performance and termination conditions.
To read the full media release click here
TLX250-CDx has not received a marketing authorisation in any jurisdiction.
[1] Positron emission tomography.
[2] Zircaix is a registered trademark of Telix Pharmaceuticals Limited in Australia; it is a trademark of Telix Pharmaceuticals Limited in the U.S. Registration status may vary by country. Brand name is subject to final regulatory approval.
[3] Imaging of prostate-specific membrane antigen with positron emission tomography.